Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2

Clinical and Investigative Medicine

Volumn 36, Issue 1, 2013, Pages

  Zhang, Hui ^a   Zhang, Jin Ying ^a   Sun, Tong Wen ^a   Shen, De Liang ^a   He, Fei ^a   Dang, Yu Hua ^a   Li, Ling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E; BENZALDEHYDE DERIVATIVE; DARAPLADIB; INTERLEUKIN 6; NEUTROPHIL COLLAGENASE; OXIME;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; BLOOD; BODY WEIGHT; CELL LINE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; MALE; METABOLISM; MOUSE; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZALDEHYDES; BLOTTING, WESTERN; BODY WEIGHT; CELL LINE; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 8; MICE; OXIMES; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84874973646     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A. Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans. Circulation. 2007; 115:2715-2721.
2. Kuniyasu A, Tokunaga M, Yamamoto T, Inoue S, Obama K, Kawahara K, Nakayama H. Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes. Biochim Biophys Acta. 2011; 1811:153-162.
3. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High- Sensitivity C-Reactive protein, Lipoprotein-Associated PhospholipaseA2, and Outcome After Ischemic Stroke. Arch Intern Med. 2006; 166:2073-2780.
4. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000; 343:1148-1155.
5. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999; 338:479-487.
6. Constantinos C. Tellis, Alexandros D. Tselepis. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009; 1791:327-338.
7. C.A. Garza, V.M. Montori, J.P. McConnell, V.K. Somers, I.J. Kullo, F. Lopez-Jimenz. Association between lipoproteinassociated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007; 82:159-165.
8. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoprotein- Associated Phospholipase A2 Activity and Incident Coronary Heart Disease Among Men and Women With Type 2 Diabetes. Diabetes. 2010; 59:1239-1243.
9. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 2006; 166:1368-1373.
10. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066.
11. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoproteinassociated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008; 118:1172-1182.
12. Liu J, Chen R, Marathe GK, Febbraio M, Zou W, McIntyre TM. Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein- Associated Phospholipase A2/PAF Acetylhydrolase. Circ Res. 2011; 108:469-477.
13. Boekholdt SM, de Winter RJ, Kastelein JJ. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiin- flammatory drugs the next frontier? Circulation. 2008; 9:1120-1122.
14. Morris KV, Rossi JJ. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 2006; 13:553-558.
15. Mäkinen PI, Koponen JK, Kärkkäinen AM, Malm TM, Pulkkinen KH, Koistinaho J, Turunen MP, Ylä-Herttuala S. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med. 2006; 8:433- 441.
16. Follenzi A, Naldini L. HIV-based vectors. Preparation and use. Methods Mol Med. 2002; 69:259-274.
17. von der Thüsen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA. Biessen EA.Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation. 2002; 105:2064-2070.
18. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P. Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor-Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation. 2001; 103:2495-2500.
19. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
20. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6:508-519.
21. Wilensky RL. Vulnerable plaque: scope of the problem. J Interv Cardiol. 2008; 21:443-451.
22. Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, Wang YP. The inhibition of lipoprotein-associated phospholipase A2 exerts benefcial effects against atherosclerosis in LDLRdefcient mice. Acta Pharmacol Sin. 2011; 32:1253-1258.
23. Chauffe RJ, Wilensky RL, Mohler ER. Recent developments with lipoprotein-associated phospholipase A2 inhibitors. Curr Atheroscler Rep. 2010; 12:43-47.
24. Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB. Increased plasma non-esterified fatty acids and plateletactivating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci. 2004; 106:421-432.
25. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAF- acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004; 177:193-201.
26. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoproteinassociated phospholipase A2: a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012; 17:289-302.
27. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res. 2003; 42:93-114.
28. Karasawa K. Clinical aspects of plasma platelet-activating factoracetylhydrolase. Biochim Biophys Acta. 2006; 1761:1359- 1372.
29. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996; 97:2784-2791.
30. Kleber ME, Wolfert RL, De Moissl GD, Grammer TB, Dietz S, Winkelmann BR, Boehm BO, März W. Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study) Clin Lab. 2011; 57:659-667.
31. Kinney GL, Snell-Bergeon JK, Maahs DM, Eckel RH, Ehrlich J, Rewers M, Hokanson JE. Liporotein-associated phospholipase A2 activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther. 2011; 13:381-387.
32. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutrition Journal. 2008; 17:7-10.
33. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22:1257-1266.
34. Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, Xiao Q, Scotland RS, Hodgkinson CP, Smith K, Willeit J, López-Otín C, Simpson IA, Kiechl S, Ahluwalia A, Xu Q, Ye S. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009; 105:921-929.
35. Häkkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ, Tew DG, Karkola K, Ylä-Herttuala S. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions, Arterioscler Thromb Vasc Biol. 1999; 19:2909-2917.
36. Sudhir K. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 2005; 90:3100-3105.